These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 18220561

  • 1. Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.
    Ragueneau-Majlessi I, Boulenc X, Rauch C, Hachad H, Levy RH.
    Curr Drug Metab; 2007 Dec; 8(8):810-4. PubMed ID: 18220561
    [Abstract] [Full Text] [Related]

  • 2. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
    Perdaems N, Blasco H, Vinson C, Chenel M, Whalley S, Cazade F, Bouzom F.
    Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
    [Abstract] [Full Text] [Related]

  • 3. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells.
    Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T.
    Eur J Pharmacol; 1998 Oct 09; 358(3):289-94. PubMed ID: 9822896
    [Abstract] [Full Text] [Related]

  • 4. Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.
    Ling SY, Huizinga RB, Mayo PR, Larouche R, Freitag DG, Aspeslet LJ, Foster RT.
    Br J Clin Pharmacol; 2014 Jun 09; 77(6):1039-50. PubMed ID: 24330024
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model.
    Rioux N, Bellavance E, Bourg S, Garneau M, Ribadeneira MD, Duan J.
    Biopharm Drug Dispos; 2013 Oct 09; 34(7):396-401. PubMed ID: 23873286
    [Abstract] [Full Text] [Related]

  • 7. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
    Ohno Y, Hisaka A, Suzuki H.
    Clin Pharmacokinet; 2007 Oct 09; 46(8):681-96. PubMed ID: 17655375
    [Abstract] [Full Text] [Related]

  • 8. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.
    Isoherranen N, Ludington SR, Givens RC, Lamba JK, Pusek SN, Dees EC, Blough DK, Iwanaga K, Hawke RL, Schuetz EG, Watkins PB, Thummel KE, Paine MF.
    Drug Metab Dispos; 2008 Jan 09; 36(1):146-54. PubMed ID: 17954524
    [Abstract] [Full Text] [Related]

  • 9. CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect.
    Boulenc X, Nicolas O, Hermabessière S, Zobouyan I, Martin V, Donazzolo Y, Ollier C.
    Eur J Drug Metab Pharmacokinet; 2016 Feb 09; 41(1):45-54. PubMed ID: 25374256
    [Abstract] [Full Text] [Related]

  • 10. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans.
    Kanazu T, Yamaguchi Y, Okamura N, Baba T, Koike M.
    Xenobiotica; 2004 May 09; 34(5):391-402. PubMed ID: 15370956
    [Abstract] [Full Text] [Related]

  • 11. PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
    Chen KF, Chan LN, Lin YS.
    J Pharmacokinet Pharmacodyn; 2020 Oct 09; 47(5):493-512. PubMed ID: 32710209
    [Abstract] [Full Text] [Related]

  • 12. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.
    Greenblatt DJ, Harmatz JS.
    Br J Clin Pharmacol; 2015 Sep 09; 80(3):342-50. PubMed ID: 25923589
    [Abstract] [Full Text] [Related]

  • 13. Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole.
    Han B, Mao J, Chien JY, Hall SD.
    Drug Metab Dispos; 2013 Jul 09; 41(7):1329-38. PubMed ID: 23584886
    [Abstract] [Full Text] [Related]

  • 14. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
    van Waterschoot RA, Rooswinkel RW, Sparidans RW, van Herwaarden AE, Beijnen JH, Schinkel AH.
    Drug Metab Dispos; 2009 Dec 09; 37(12):2305-13. PubMed ID: 19752211
    [Abstract] [Full Text] [Related]

  • 15. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G, Moton A, Ma L, Savant I, Martinho M, Seiberling M, McLeod J.
    Clin Ther; 2009 Feb 09; 31(2):286-98. PubMed ID: 19302901
    [Abstract] [Full Text] [Related]

  • 16. Simultaneous evaluation of substrate-dependent CYP3A inhibition using a CYP3A probe substrates cocktail.
    Lee E, Shon JC, Liu KH.
    Biopharm Drug Dispos; 2016 Sep 09; 37(6):366-72. PubMed ID: 27323294
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
    Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE.
    Clin Pharmacol Ther; 2013 Jun 09; 93(6):564-71. PubMed ID: 23511711
    [Abstract] [Full Text] [Related]

  • 19. Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers.
    Brings A, Lehmann ML, Foerster KI, Burhenne J, Weiss J, Haefeli WE, Czock D.
    Br J Clin Pharmacol; 2019 Jul 09; 85(7):1528-1537. PubMed ID: 30912163
    [Abstract] [Full Text] [Related]

  • 20. Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity.
    Stoll F, Burhenne J, Lausecker B, Weiss J, Thomsen T, Haefeli WE, Mikus G.
    J Clin Pharmacol; 2013 Nov 09; 53(11):1199-204. PubMed ID: 23939663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.